Portal de Periódicos da CAPES

Relationship Between Tumor Size and the Curability of Metastatic Prostatic Cancer by Surgery Alone or in Combination With Adjuvant Chemotherapy

1988; Lippincott Williams & Wilkins; Volume: 139; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(17)42800-x

1527-3792

John M. Henry, John T. Isaacs,

Renal cell carcinoma treatment

No AccessJournal of Urology1 May 1988Relationship Between Tumor Size and the Curability of Metastatic Prostatic Cancer by Surgery Alone or in Combination With Adjuvant Chemotherapy John M. Henry, and John T. Isaacs John M. HenryJohn M. Henry , and John T. IsaacsJohn T. Isaacs View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)42800-XAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The MAT-Lu subline of the Dunning R3327 system of rat prostatic adenocarcinomas universally metastasizes to the lungs of untreated recipient hosts. The MAT-Lu cancer was implanted into the hind leg of animals and the primary tumor was allowed to grow to various sizes before the tumor bearing leg was surgically removed. These studies demonstrated that there is a direct relationship between the size of the primary tumor at the time of surgical removal and the number of metastases already established in the lungs. Once the primary MAT-Lu reaches a size of >0.5 cc, >50% of all inoculated animals already have established lung metastases and are thus not cured by surgery alone. In an attempt to increase the cure rates, adjuvant chemotherapy (cytoxan given at a dose of 90mg./kg. body weight) was used in combination with surgery. These studies demonstrated that if chemotherapy was given by itself to animals bearing macroscopically established (>0.5 cc) MAT-Lu cancers, no animals could be cured. In direct contrast, by combining the same intensity of adjuvant chemotherapy with the removal of the primary MAT-Lu cancer, cures could be produced in high (>90%) frequency, but only if this combinational approach was simultaneously initiated when the primary tumor was 2 cc) or if the chemotherapy was delayed following surgery (both processes allowing the metastatic tumor burden to increase before initiating adjuvant chemotherapy), the ability of the adjuvant chemotherapy to cure the host of its metastatic tumor burden is lost. These results demonstrate that the MAT-Lu rat prostatic cancer, like human prostatic cancer, is not effectively treated by chemotherapy alone or by adjuvant chemotherapy combined with surgery if the treatment is given too late in the course of the disease. These studies emphasize the critical requirement of combining surgery and adjuvant chemotherapy as early as possible in the treatment of metastatic prostatic cancer in order to minimize the total metastatic tumor burden and maximize the possibility of cure. © 1988 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited BySwanson G, Thompson I, Basler J and Crawford E (2018) Metastatic Prostate Cancer—Does Treatment of the Primary Tumor Matter?Journal of Urology, VOL. 176, NO. 4, (1292-1298), Online publication date: 1-Oct-2006.ZINCKE H, LAU W, BERGSTRALH E and BLUTE M (2018) ROLE OF EARLY ADJUVANT HORMONAL THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, VOL. 166, NO. 6, (2208-2215), Online publication date: 1-Dec-2001.WALSH P, DEWEESE T and EISENBERGER M (2018) A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENTJournal of Urology, VOL. 166, NO. 2, (508-516), Online publication date: 1-Aug-2001.Seay T, Blute M and Zincke H (2018) LONG-TERM OUTCOME IN PATIENTS WITH pTxN+ ADENOCARCINOMA OF PROSTATE TREATED WITH RADICAL PROSTATECTOMY AND EARLY ANDROGEN ABLATIONJournal of Urology, VOL. 159, NO. 2, (357-364), Online publication date: 1-Feb-1998.Moulinoux J, Quemener V, Cipolla B, Guillé F, Havouis R, Martin C, Lobel B and Seiler N (2018) The Growth of MAT-LyLu Rat Prostatic Adenocarcinoma can be Prevented in Vivo by Polyamine DeprivationJournal of Urology, VOL. 146, NO. 5, (1408-1412), Online publication date: 1-Nov-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Van moorselaar R, Beniers A, Hendriks B, Van Der Meide P, Schellekens H, Debruyne F and Schalken J (2018) In Vivo Antiproliferative Effects of Gamma-Interferon and Tumor Necrosis Factor Alpha in a Rat Renal Cell Carcinoma Model SystemJournal of Urology, VOL. 143, NO. 6, (1247-1251), Online publication date: 1-Jun-1990. Volume 139Issue 5May 1988Page: 1119-1123 Advertisement Copyright & Permissions© 1988 by The American Urological Association Education and Research, Inc.MetricsAuthor Information John M. Henry More articles by this author John T. Isaacs More articles by this author Expand All Advertisement PDF DownloadLoading ...